Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-05-31
2011-12-13
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C514S021600
Reexamination Certificate
active
08076453
ABSTRACT:
The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B1receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis. Formula (I): aay-aax-aa0-aa1-aa2-aa3-aa4-aa5-Ser6-Pro7-D-Phe8-X.
REFERENCES:
patent: 5541286 (1996-07-01), Kyle
patent: 5552383 (1996-09-01), Kyle et al.
patent: 5686565 (1997-11-01), Kyle et al.
patent: 5817756 (1998-10-01), Kyle et al.
Rhaleb, N. et al., Structure-activity studies on bradykinin and related peptides: agonists, Br. J. Pharmacol, 1990, 445-448, 99.
Audet, R. et al., Cardiovascular Effects of Sar-[D-Phe8]des-Arg9-Bradykinin, a Metabolically Protected Agonist of B1 Receptor for Kinins, in the Anesthetized Rabbit Pretreated with a Sublethal Dose of Bacterial Lipopolysaccharide, J. Pharmacol Exp Ther, 1997, 6-15, 280-1.
Drapeau, G. et al. Hypothensive effects of Lys-des-Arg9-Bradykinin and metabolically protected agonists of B1 receptors for Kinins, J. Pharmacol Exp Ther, 1991, 997-1003, 259-3.
Nicolau, M. et al., Induction of bradykinin B1 hypotensive receptors in rats by lipopolysaccharide, Can. J. Physiol. Pharmacol., 1996, 337-340, 74.
Prat, A. et al., Kinin B1 receptor expression and function on human brain endothelial cells, J. Neuropathol Exp Neurol., 2000, 896-906, 59.
Cardoso, R.C. et al., Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model, BMC Neuroscience, 2004, 38-5.
Agata, J. et al., Bradykinin B1 Receptor Mediates Inhibition of Neointima Formation in Rat Artery After Balloon Angioplasty, Hypertension, 2000, 364-370, 36.
Black, K.L. et al., Biochemical opening of the blood-brain barrier, Adv. Drug Delivery Rev. 1995, 37-52, 15.
Bouchard J.F. et al., Role of kinins in the endothelial protective effect of ischaemic preconditioning, Brit J Pharmacology, 1998, 413-420, 123.
Chahine et al., Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor, Brit J Pharmacology, 1993, 318-322, 108.
Duguay D. et al., Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor, Brit J Pharmacology, 2004, 728-736-322, 141.
Couture R. and Girolami J.P., Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus, Eur. J. Pharmacol 2004, 467-485, 500(1-3).
Duka, I. et al. Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension, Circ. Res., 2001, 275-281, 88.
Duka A. et al. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation, Am. J. Physiol Endocrinol. Metab., 2006, 268-274, 291.
Emmanueli, C., and Madeddu, P., Targeting kinin receptors for the treatment of tissue ischaemia, Trend in Pharmacol. Sci. 2001, 478-484, 22.
Emmanueli, C. et al., Targeting Kinin B1 Receptor for Therapeutic Neovascularization, Circulation. 2002, 360-366, 105.
Emerich, F.E. et al., Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain, Pharm. Res., 2000, 1212-1219, 17.
Kichuck, M., Regulation of Nitric Oxide Production in Human Coronary Microvessels and the Contribution of Local Kinin Formation, Circulation, 1996, 44-51, 94.
Emerich, D.F., et al., Bradykinin Modulation of Tumor Vasculature: I. Activation of B2 Receptors Increases Delivery of Chemotherapeutic Agents into Solid Peripheral Tumors, Enhancing Their Efficacy, J Pharmacol Exp Ther, 2001, 623-631, 296.
Gobeil Jr, F. et al., Receptors for kinins in the human isolated umbilical vein, Brit. J. Pharmacol, 1996, 289-294, 118.
Gobeil Jr, F. et al. Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657), Immunopharmacol, 1999, 179-185, 43.
Gobeil Jr, F. et al., Kinin B1 Receptor Antagonists Containing {alpha}-Methyl-L-Phenylalanine: In Vitro and In Vivo Antagonistic Activities, Hypertension, 1999, 823-829, 33.
Hagiwara, M. et al., Renal Protective Role of Bradykinin B1 Receptor in Stroke-Prone Spontaneously Hypertensive Rats,Hypertens. Res., 2004, 399-408, 27.
Mathieu D. et al., The Importance of a Syngeneic Glioma Implantation Model: Comparison of the F98 Cell Line in Fischer and Long-Evans Rats, J. Appl. Res., 2005, 17-25, 5.
Parenti, A., et al. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway, FASEB J. 2001, 1487-1489, 15.
Sharma, J.N and Thani, R.B., Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases, IDrug, 2004, 926-934, 7.
Tramontana, M. et al., Differences between Peptide and Nonpeptide B2 Bradykinin Receptor Antagonists in Blocking Bronchoconstriction and Hypotension Induced by Bradykinin in Anesthetized Guinea Pigs, J Pharmacol Exp Ther, 2001, 1051-1057, 296.
Xu, J. et al., Role of the B1 Kinin Receptor in the Regulation of Cardiac Function and Remodeling After Myocardial Infarction, Hypertension, 2005, 747-753, 45.
Rhaleb et al., ‘Structure-activity studies on bradykinin and related peptides: Agonists’ British Journal of Pharmacology vol. 99, 1990, pp. 445-448, XP008073361.
Audet et al.: ‘Cardiovascular effects of Sar-[D-Phe8]des-Arg9-bradykinin, a metabolically protected agonist of B1 receptor for kinins, in the anesthetized rabbit pretreated with a sublethal dose of bacterial lipopolysaccharide’ The Journal of Pharmacology and Experimental Therapeutics vol. 280, No. 1, 1997, pp. 6-15, XP003004845.
Drapeau et al.: ‘Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins’ Journal of Pharmacology and Experimental Therapeutics vol. 259, No. 3, 1991, pp. 997-1003, XP008073351.
Nicolau et al.: ‘Induction of bradykinin B1 hypotensive receptors in rats by lipopolysaccharide’ Can. J. Physiol. Pharmacol. vol. 74, 1996, pp. 337-340, XP008073360.
Prat et al.: ‘Kinin B1 receptor expression and function on human brain endothelial cells’ Journal of Experimental Neurology vol. 59, No. 10, 2000, pp. 896-906, XP008073350.
Cardoso et al.: ‘Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]desArg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model’ BMC Neuroscience vol. 5, No. 38, Sep. 30, 2004, p. 38, XP002102871.
Neugebauer W A et al: “Kinin B1 receptor antagonists with metabolic stability” Journal of Peptide Science, vol. 8, No. Supplement, 2002, p. S123, XP002557001 & 27th European Peptide Symposium; Sorrento, Italy; Aug. 31-Sep. 6, 2002 ISSN: 1075-2617.
Cote J et al: “Novel kinin B1 receptor agonists with improved pharmacological profiles” Peptides, Elsevier, Amsterdam, vol. 30, No. 4, Apr. 1, 2009, pp. 788-795, XP026070661 ISSN: 0196-9781 [retrieved on Dec. 27, 2008].
Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, et al. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 2005;45:747-53.
Moniwa N, Agata J, Hagiwara M, Ura N, Shimamoto K. The role of bradykinin B1 receptor on cardiac remodeling in stroke-prone spontaneously hypertensive rats (SHR-SP). Biol Chem. 2006;387(2):203-9.
Tschope C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, et al. The bradykinin B1 receptor contributes to
Fortin David
Gobeil, Jr. Fernand
Neugebauer Witold A.
Regoli Domenico
Bereskin & Parr LLP / S.E.N.C.R.L., s.r.l.
Lukton David
Societe De Commercialisation Des Produits De La Recheche Appliqu
LandOfFree
Kinin B 1 receptor peptide agonists and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinin B 1 receptor peptide agonists and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinin B 1 receptor peptide agonists and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306696